Wilson's Disease| A Pipeline Analysis Report 2018| Technavio

Technavio has published a new report on the drug development pipeline for Wilson’s disease, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

LONDON--()--Technavio has announced their latest pipeline analysis report on the Wilson's disease market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat Wilson’s disease.

This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Wilson's disease: Market overview

Wilson's disease, also known as hepatolenticular degeneration, is a rare genetic metabolic disorder in which excessive copper ions start accumulating in various body parts such as the liver, brain, and eyes. The tissues and organs get damage due to the toxic effect of high levels of copper ions. Chronic liver disease, central nervous system (CNS) abnormalities, and psychiatric (mental health related) disturbances are some of the signs and symptoms of Wilson’s disease. Mutation of the ATP7B gene, which is responsible for encoding an ATP7B protein, is the primary cause of the disorder. Although there is no cure for this disease, some therapies help to reduce or control the amount of copper accumulates in the body.

According to a senior market research analyst at Technavio, “Wilson’s disease can affect various parts of the body. Sometimes, the symptoms in some people may not be seen unless they face acute liver failure suddenly. Affected people also go through a variety of neurological signs and symptoms. Neurological features often develop after the liver has retained a significant amount of copper, however, it has been observed in some people with little or no liver damage.”

Wilson's disease: Segmentation analysis

This pipeline analysis report segments the Wilson's disease market based on therapies employed (monotherapy), RoA (oral and intravenous), therapeutic modality (small molecule and gene therapy), targets (ATP7B protein), MoA (copper chelation, ATP7B protein enhancer, copper-protein complex formation ), geographical segmentation (EMEA and the Americas) and recruitment status (active, not recruiting and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

In the current pipeline under RoA, 50% of the molecules that are being investigated for the treatment of Wilson's disease are oral.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Release Summary

Technavio has published a new report on the drug development pipeline for Wilson’s disease, including a detailed study of the pipeline molecules.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com